1.1Direct sigma receptor modulation
A tetrahydroindazole ligand occupies the sigma-1 receptor binding pocket and modulates receptor activity through occupancy. Ligand concentration controls occupancy at a fixed receptor abundance.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A tetrahydroindazole ligand occupies the sigma-1 receptor binding pocket and modulates receptor activity through occupancy. Ligand concentration controls occupancy at a fixed receptor abundance.
A cysteine-reactive recruiter attaches covalently to RNF114 and carries a tethered sigma receptor ligand. The tether brings the recruited ligase near the bound receptor and positions its associated ubiquitin-conjugating enzyme for transfer to accessible lysines.
The ligase binder and the receptor binder each attach to one member of a complementary pair of coiled-coil peptides. In a reconstituted assay, the peptides form a heterodimer that holds the two binders together through hydrophobic packing and ionic contacts.
The receptor-binding scaffold is 4-phenyl-1-(4-phenylbutyl)piperidine. The protonatable piperidine nitrogen supplies a basic center, and the two phenyl groups provide hydrophobic contacts in the receptor pocket.
In 2-(morpholin-4-yl)ethyl 1-phenylcyclohexane-1-carboxylate, the morpholine oxygen occupies the ring position opposite the basic nitrogen. The nitrogen supplies the protonatable center, and the phenylcyclohexyl group supplies the hydrophobic portion of the ligand.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Use a tetrahydroindazole conjugate with a cereblon-binding group as a reference perturbation in the development of cell imaging assays. Apply the conjugate, the unconjugated receptor ligand, and vehicle to separate wells of a culture plate. Fix the cells, stain for the selected sigma receptor and nuclei, and compare per-cell receptor fluorescence with receptor abundance measured by immunoblotting.
Replace the ligase-binding group with an aryl sulfonamide that recruits the DCAF15 ubiquitin ligase complex. Join an aryl sulfonamide derivative and a tetrahydroindazole receptor ligand through a flexible linker, using attachment positions that retain binding to each protein. Measure ligase binding and receptor binding separately, then compare receptor abundance in parental cells and cells depleted of DCAF15.
Prepare four conjugates with the same tetrahydroindazole ligand and cereblon-binding group joined by linkers containing 2, 4, 6, or 8 ethylene glycol units. Keep both attachment positions and terminal amide connections fixed across the series. Expose cells to 0.03, 0.3, and 3 micromolar of each conjugate for 4 and 24 hours, then measure receptor abundance and viable cell count.
Integrate a tetrahydroindazole conjugate with a perfused microfluidic culture chip containing receptor-expressing cells in parallel channels. Perfuse one channel with conjugate and a second with vehicle, then switch both channels to compound-free medium. Fix replicate channels at the end of exposure and at successive washout times, then quantify receptor staining per cell to measure depletion and recovery.
Couple a tetrahydroindazole conjugate exposure assay to targeted liquid chromatography–tandem mass spectrometry. Treat cells that express both sigma receptors, isolate a membrane-enriched fraction, and digest its proteins with trypsin. Add stable-isotope-labeled peptide standards for unique peptides from each receptor and quantify the endogenous peptides against their standards. Report abundance changes for both receptors alongside a membrane protein recovery control.
Use a robotic liquid handler to dispense serial dilutions of each conjugate into replicate plates seeded with receptor-expressing cells. Stagger dosing so all plates reach their assigned exposure times at one collection point, then fix and stain for the receptor and nuclei. Segment cells from the nuclear images, normalize receptor fluorescence to vehicle wells on each plate, and fit concentration-response curves for each exposure time. Flag wells with low cell counts so declines in cell number remain visible alongside changes in receptor signal.
A glutarimide-containing moiety binds cereblon through its cyclic imide group. An exocyclic amino group on the adjoining aromatic ring provides an attachment point for the linker.
A triethylene glycol-derived spacer carries an amide at each end. One amide connects the spacer to the ligase-binding moiety, and the other connects it to the receptor-binding moiety.
A ring nitrogen occupies X in the receptor-binding scaffold. The nitrogen replaces the carbon and its attached hydrogen at that position and supplies a lone pair.
A methyl group occupies R4 on the receptor-binding scaffold. The substituent adds one carbon and presents a small hydrophobic surface at that site.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In an additional aspect, the disclosure provides bifunctional or PROTAC compounds, which comprise an E3 Ubiquitin Ligase binding moiety (i.e., a ligand for an E3 Ubiquitin Ligase or “ULM” group), and a moiety that binds a target protein (i.e., a protein/polypeptide targeting ligand or “PTM” group) such that the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.A · US 2018/0215731 A1 · ¶ 15
In certain embodiments, the compound comprises an ILM or a VLM or a CLM or a MLM coupled, e.g., linked covalently, directly or indirectly, to a moiety that binds a target protein (i.e., a protein targeting moiety or a “PTM”). In certain embodiments, the ILM/VLM/CLM/MLM and PTM are joined or coupled via a chemical linker (L).B · US 2018/0256586 A1 · ¶ 65
In certain aspects, the present disclosure provides compounds which comprise a ligand, e.g., a small molecule ligand (i.e., having a molecular weight of below 2,000, 1,000, 500, or 200 Daltons), which is capable of binding to a ubiquitin ligase, such as IAP, VHL, MDM2, or cereblon.A · US 2018/0215731 A1 · ¶ 30
In another embodiment, the present disclosure is directed to a compound which comprises a PTM group, which binds to a target protein or polypeptide, which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to the ULM group (such as CLM) or through a linker moiety L, or PTM is alternatively a ULM′ group (such as CLM′) which is also a ubiquitin ligase binding moiety, which may be the same or different than the ULM group as described above and is linked diA · US 2018/0215731 A1 · ¶ 178
Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest.A · US 2018/0215731 A1 · ¶ 192
R26 of OR26 is an optionally substituted alkyl, wherein the optional substituents are OH, halogen or NH2; and m is an integer from 1-8, R3 and R4 of Formula (XXVII) and (XXVIII) are independently selected from an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heteroaryB · US 2018/0256586 A1 · ¶
An empty cell means only that no passage was reproduced there.
The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure.A · US 2018/0215731 A1 · ¶ 3
On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved.A · US 2018/0215731 A1 · ¶ 4
The bifunctional compounds are useful as modulators of targeted ubiquitination of FLT3 (and mutants thereof), which is degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure.B · US 2018/0256586 A1 · ¶ 4
On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved.B · US 2018/0256586 A1 · ¶ 5
patent.fyi, US 2026/0356807 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356807/, SHA-256 52a478df2ba140cb36a4e9811fcf7a08a007f607ed5b8f731ffe8ff5ddcae037